EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia

Sumiko Gomi iD, Emily Price, Hailey Burgoyne, Sabrina Faozia, Eva Katahira, Eric McIndoo, Anyauba A Nmaju, Kavita Sharma, Ali Aghazadeh-Habashi, Amy E Bryant, Dennis L Stevens, Jessica V Pierce und 2 weitere

Antimicrobial Agents and Chemotherapy · 03.09.2025 · 69 (9)

DOI: 10.1128/aac.00469-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.09.2025. Verfasst von Sumiko Gomi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Idaho Veterans Research and Education Foundation, Boise, Idaho, USA. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents, Pneumonia, Staphylococcal, Tetracyclines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, U.S. Department of Veterans Affairs, Paratek Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-influenza Staphylococcus aureus pneumonia, particularly methicillin-resistant S. aureus (MRSA), remains a major cause of mortality, highlighting the urgent need for newer therapeutic options. Omadacycline is an aminomethylcycline antibiotic that has demonstrated efficacy against MRSA across many infection models, but its potential in post-influenza A virus (IAV)-MRSA pneumonia remains unexplored. Using a murine model of this infection, we evaluated the effects of omadacycline and a comparator antibiotic, linezolid, on survival, inflammation, bacterial load, toxin production, and lung histopathology. In survival studies, omadacycline matched the effectiveness of oral linezolid at clinically relevant doses. In addition, both antibiotics, particularly omadacycline, attenuated the production of multiple pro-inflammatory cytokines and reduced neutrophil infiltration in the lungs, independent of their effects on pulmonary microbial burden, suggesting an immunomodulatory mechanism of action. Panton-Valentine leukocidin (PVL) toxin production in vitro and in vivo was also assessed, and while the role of PVL in this murine model remains unclear, both agents reduced PVL production. These findings provide the first preclinical demonstration of in vivo efficacy for omadacycline against IAV-MRSA pneumonia and its ability to modulate the host immune response, thereby reducing the excessive inflammation that is linked to mortality in this disease state. Further investigation into the precise interplay between omadacycline and immunomodulation in this disease state is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsPneumonia, StaphylococcalTetracyclinesAnti-Inflammatory AgentsAnimalsMiceLinezolidDisease Models, AnimalBacterial ToxinsLeukocidinsExotoxinsLungFemaleCytokines

Stichwörter der Autor:innen

MRSAcytokinesimmune responseinfluenzamouse modelomadacyclinepneumonia

Substanzen

LinezolidAnti-Bacterial AgentsTetracyclinesomadacyclineBacterial ToxinsLeukocidinsPanton-Valentine leukocidinExotoxinsAnti-Inflammatory AgentsCytokines

Autor:innen und Institutionen

  • Idaho Veterans Research and Education Foundation, Boise, Idaho, USA.
  • Veterans Affairs Medical Center, Boise, Idaho, USA.
  • Boise State University, Boise, Idaho, USA.
  • Idaho State University, Meridian, Idaho, USA.
  • Idaho State University, Pocatello, Idaho, USA.
  • University of Washington, Seattle, Washington, USA.

ORCID-Profile: Sumiko Gomi, Alisa W Serio, Sarah E Hobdey

Förderung

  • NIGMS NIH HHS
  • U.S. Department of Veterans Affairs
  • Paratek Pharmaceuticals Inc
  • National Institute of General Medical Sciences

Zitieren

APA

Gomi, S., Price, E., Burgoyne, H., Faozia, S., Katahira, E., McIndoo, E., Nmaju, A. A., Sharma, K., Aghazadeh-Habashi, A., Bryant, A. E., Stevens, D. L., Pierce, J. V., Serio, A. W., & Hobdey, S. E. (2025). Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia. Antimicrobial Agents and Chemotherapy, 69(9). https://doi.org/10.1128/aac.00469-25

Vancouver

Gomi S, Price E, Burgoyne H, Faozia S, Katahira E, McIndoo E, et al. Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia. Antimicrobial Agents and Chemotherapy. 2025;69(9). doi:10.1128/aac.00469-25

BibTeX
@article{Gomi2025,
  author = {Gomi, Sumiko and Price, Emily and Burgoyne, Hailey and Faozia, Sabrina and Katahira, Eva and McIndoo, Eric and Nmaju, Anyauba A and Sharma, Kavita and Aghazadeh-Habashi, Ali and Bryant, Amy E and Stevens, Dennis L and Pierce, Jessica V and Serio, Alisa W and Hobdey, Sarah E},
  title = {Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {9},
  doi = {10.1128/aac.00469-25}
}
Kostenlos starten →